Fludarabine and Cytarabine as a Sequential Infusion Regimen for Treatment of Adults with Recurrent, Refractory or Poor Prognosis Acute Leukemia

摘要: We did a retrospective analysis on the safety and efficacy of sequential infusion fludarabine cytosine arabinoside (ara-C) in treating refractory, recurrent or poor prognosis acute leukemia adult patients. Forty-five patients with myelogenous (AML) lymphoblastic (ALL) received total 68 courses continuous for 2 days (total dose 71.5 mg/m(2) ) followed by 3 ara-C 7590 ). Thirty-nine had refractory disease, six other adverse prognostic features. Thirty-six AML, seven ALL, two CML blastic phase. Complete remission was seen 20 (44%), partial 5 (11%), giving response rate 56%, similar both AML ALL. Duration to prior therapy not affect rate. All Philadelphia chromosome positive ALL obtained complete remission. Median duration 4.7 months (range 0.6-36.6), median overall survival 5.0 (0.7-40+). 10.1 responders. Pulmonary toxicity 8 patients, whom died from respiratory distress syndrome. No cardiac observed, but transient cerebellar toxicity. Profound myelosuppression all conclude that is an effective non-cardiotoxic regimen adults leukemia, may be particularly useful resistant warrant further investigation this subset. rather than neurological unique side effect regimen.